表紙
市場調査レポート

HPV/パップ検査の世界市場 2020年までの予測:検査種類 (追跡検査、同時検査、一次検査)・用途 (子宮頚癌、膣癌)・エンドユーザー・地域別

HPV Testing & Pap Test Market by Test Type (HPV Testing (Follow-Up, Co-Testing, Primary)), by Application (Pap Test (Cervical Cancer, Vaginal Cancer)), by End User (Laboratories, Hospitals, Physicians' Offices & Clinics) - Global Forecast to 2020

発行 MarketsandMarkets 商品コード 352332
出版日 ページ情報 英文 126 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
HPV/パップ検査の世界市場 2020年までの予測:検査種類 (追跡検査、同時検査、一次検査)・用途 (子宮頚癌、膣癌)・エンドユーザー・地域別 HPV Testing & Pap Test Market by Test Type (HPV Testing (Follow-Up, Co-Testing, Primary)), by Application (Pap Test (Cervical Cancer, Vaginal Cancer)), by End User (Laboratories, Hospitals, Physicians' Offices & Clinics) - Global Forecast to 2020
出版日: 2016年02月12日 ページ情報: 英文 126 Pages
概要

世界のHPV/パップ検査市場のうち、現段階ではパップ検査の方が市場シェアが高くなっていますが、試験の正確性・感度の問題から、HPV検査に移行する動きが広がっており、今後はパップ検査 (パパロニコウ試験) の市場縮小が生じると見られています。他方、子宮頚癌の発症件数増加や、HPV (ヒトパピローマウイルス) 診断の認知度の改善、HPV一次検査の普及などに伴い、HPV検査市場は今後大幅に成長する見通しです。エンドユーザー別に見ると、検査室向け需要が最大のシェアを占めるほか、病院向け需要も今後大きく増加すると見られています。

当レポートでは、世界のHPV (ヒトパピローマウイルス) 検査およびパップテストの市場について分析し、市場の基本的構造や最新動向、主な市場促進・阻害要因、市場動向と今後の見通し (過去2年間・今後6年間分)、検査の種類別・用途別・エンドユーザー別・地域別の詳細動向、市場競争の状態、今後の技術開発・市場発展の方向性、主要企業のプロファイルなどを調査・考察しております。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場の内訳
  • 市場のダイナミクス
    • 促進要因
      • 子宮頚癌の発症件数増加と人口高齢化
      • 子宮頚癌検診プログラムの認知度の上昇
      • 各国政府による促進策と資金援助
    • 抑制要因
      • 子宮頚癌検診の規制ガイドラインの改定
      • HPVワクチン投与
    • 市場機会
      • HPV一次検診の導入
    • 課題
      • 不確実な医療費償還シナリオ

第6章 HPV/パップ検査市場:検査の種類別

  • イントロダクション
  • HPV (ヒトパピローマウイルス) 検査
  • HPVの追跡検査
  • 同時検査
  • 一次HPV検査
  • パップ検査

第7章 パップ検査市場:用途別

  • イントロダクション
    • 子宮頚癌検診 (スクリーニング)
    • 膣癌検診

第8章 HPV/パップ検査市場:エンドユーザー別

  • イントロダクション
  • 試験室
  • 病院
  • 開業医・診療所

第9章 HPV/パップ検査市場:地域別

  • イントロダクション
  • 北米 (米国、カナダ)
  • 欧州
  • アジア太平洋地域 (日本、中国、インドなど)
  • 他の国々 (RoW)

第10章 競争環境

  • 概要
  • 市場シェア分析:世界のHPV/パップ検査市場
    • 製品の認証とライセンス
    • 新製品の上市
    • 契約・事業提携・事業協力
    • 企業買収
    • 事業拡張

第11章 企業プロファイル (概要、製品・サービス、財務状況、戦略、近年の動向)

  • イントロダクション
  • ABBOTT LABORATORIES
  • QIAGEN N.V.
  • ROCHE DIAGNOSTICS
  • HOLOGIC, INC.
  • BECTON, DICKINSON AND COMPANY
  • QUEST DIAGNOSTICS
  • ONCO HEALTH CORPORATION
  • SEEGENE, INC.
  • FEMASYS INC.
  • ARBOR VITA CORPORATION

第12章 付録

図表一覧

目次
Product Code: MD 4083

Increasing awareness of cervical cancer screening programs, and government initiative and funding are the Major Drivers of the HPV testing and Pap test Market

On the basis of test type, the HPV testing and Pap test market is divided into two major segments, namely, HPV testing and Pap test. The HPV testing segment is further classified into three sub-segments, namely, follow-up HPV testing, co-testing, HPV primary testing. The Pap test segment is expected to account for the largest share of the HPV testing and Pap test market in 2015. But this segment is projected to decline at a negative during the forecast period due to due the shift towards the use of HPV testing, as it provides enhanced accuracy and sensitivity than Pap test. Furthermore, the HPV testing segment is expected to grow at the highest CAGR in the next five years, owing to increasing incidences of cervical cancer, raising awareness of HPV screening, as well as the introduction of HPV primary test.

On the basis of type of application, the global HPV testing and Pap test market is classified into two major segments, namely, cervical cancer screening and vaginal cancer screening. The cervical cancer screening application segment is expected account for the largest share of the Pap test market in 2015. This large share can be attributed to the increasing incidences of cervical cancer and government initiatives to spread the awareness about cervical cancer screening.

On the basis of type of end user, the HPV testing and Pap test market is classified into three segments, namely, hospitals, laboratories, physicians' offices and clinics. The laboratories end-user segment is expected to account for the largest share of the HPV testing and Pap test market in 2015. Furthermore, the hospitals end-user segment is expected to grow at the highest CAGR in the next five years, as most of the diagnostic tests are carried out in-house in hospitals with advanced technologies in shorter period of time.

From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market sizes and data of the various segments in this industry. It focuses on emerging and high-growth segments, high-growth regions, and initiatives by governments. The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on the key players in the HPV testing and Pap test market and the strategies adopted by them to maintain and increase their market shares in the near future. The above mentioned market research data, current market size, and forecast of the future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on cervical cancer screening tests offered by top 10 players in the HPV testing and Pap test market. The report analyzes the HPV testing and Pap test market by product, application, and end user across geographies
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the HPV testing and Pap test market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for HPV testing and Pap test across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HPV testing and Pap test market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the HPV testing and Pap test market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. STUDY SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
      • 2.2.2.1. Key Industry Insights
    • 2.2.3. ASSUMPTIONS

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. HPV TESTING AND PAP TEST MARKET OVERVIEW
  • 4.2. HPV TESTING AND PAP TEST MARKET, BY TEST TYPE
  • 4.3. HPV TESTING MARKET, BY TEST TYPE AND END USER
  • 4.4. HPV TESTING AND PAP TEST MARKET, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. Increasing number of cervical cancer cases and growing aging population
      • 5.3.1.2. Increasing awareness of cervical cancer screening programs
      • 5.3.1.3. Government initiatives and funding
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Changes in regulatory guidelines for cervical cancer screening
      • 5.3.2.2. HPV Vaccination
    • 5.3.3. OPPORTUNITY
      • 5.3.3.1. Introduction of HPV primary screening tests
    • 5.3.4. CHALLENGE
      • 5.3.4.1. Uncertain reimbursement scenario

6. HPV TESTING AND PAP TEST MARKET, BY TEST TYPE

  • 6.1. INTRODUCTION
  • 6.2. HPV TESTING
  • 6.3. FOLLOW-UP HPV TESTING
  • 6.4. CO-TESTING
  • 6.5. PRIMARY HPV TESTING
  • 6.6. PAP TEST

7. PAP TEST MARKET, BY APPLICATION

  • 7.1. INTRODUCTION
    • 7.1.1. CERVICAL CANCER SCREENING
    • 7.1.2. VAGINAL CANCER SCREENING

8. HPV TESTING AND PAP TEST MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. LABORATORIES
  • 8.3. HOSPITALS
  • 8.4. PHYSICIANS' OFFICES AND CLINICS

9. HPV TESTING AND PAP TEST MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. U.S.
    • 9.2.2. CANADA
  • 9.3. EUROPE
  • 9.4. ASIA-PACIFIC
    • 9.4.1. JAPAN
    • 9.4.2. CHINA
    • 9.4.3. INDIA
    • 9.4.4. REST OF ASIA-PACIFIC
  • 9.5. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

  • 10.1. OVERVIEW
  • 10.2. MARKET SHARE ANALYSIS, GLOBAL HPV TESTING AND PAP TEST MARKET
    • 10.2.1. PRODUCT APPROVALS AND LICENSES
    • 10.2.2. NEW PRODUCT LAUNCHES
    • 10.2.3. AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 10.2.4. ACQUISITIONS
    • 10.2.5. EXPANSIONS

11. COMPANY PROFILE (Overview, Products and Services, Financials, Strategy & Development)*

  • 11.1. INTRODUCTION
  • 11.2. ABBOTT LABORATORIES
  • 11.3. QIAGEN N.V.
  • 11.4. ROCHE DIAGNOSTICS
  • 11.5. HOLOGIC, INC.
  • 11.6. BECTON, DICKINSON AND COMPANY
  • 11.7. QUEST DIAGNOSTICS
  • 11.8. ONCO HEALTH CORPORATION
  • 11.9. SEEGENE, INC.
  • 11.10. FEMASYS INC.
  • 11.11. ARBOR VITA CORPORATION

*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

12. APPENDIX

  • 12.1. INSIGHTS OF INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 12.4. AVAILABLE CUSTOMIZATIONS
  • 12.5. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: INCREASING NUMBER OF CERVICAL CANCER CASES AND GROWING AGING POPULATION DRIVE THE HPV TESTING AND PAP TEST MARKET
  • TABLE 2: CHANGES IN REGULATORY GUIDELINES FOR CERVICAL CANCER SCREENING ACTS A RESTRAINING FACTOR HAMPERING THE MARKET GROWTH
  • TABLE 3: INTRODUCTION OF HPV PRIMARY SCREENING TESTS PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES FOR THE HPV TESTING AND PAP TEST MARKET
  • TABLE 4: UNCERTAIN REIMBURSEMENT SCENARIO IS LIMITING THE GROWTH FOR THE HPV TESTING AND PAP TEST MARKET
  • TABLE 5: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 6: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (MILLION TESTS)
  • TABLE 7: HPV TESTING MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 8: HPV TESTING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 9: HPV TESTING MARKET SIZE, BY REGION, 2013-2020 (MILLION TESTS)
  • TABLE 10: NORTH AMERICA: HPV TESTING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 11: ASIA-PACIFIC: HPV TESTING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 12: FOLLOW-UP HPV TESTING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 13: HPV CO-TESTING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 14: PAP TEST MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 15: PAP TEST MARKET SIZE, BY REGION, BY VOLUME 2013-2020 (MILLION TESTS)
  • TABLE 16: NORTH AMERICA: PAP TEST MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 17: ASIA-PACIFIC: PAP TEST MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 18: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 19: CERVICAL CANCER SCREENING MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 20: NORTH AMERICA: CERVICAL CANCER SCREENING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 21: ASIA-PACIFIC: CERVICAL CANCER SCREENING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 22: VAGINAL CANCER SCREENING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 23: ASIA-PACIFIC: VAGINAL CANCER SCREENING MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 24: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 25: HPV TESTING AND PAP TEST MARKET SIZE FOR LABORATORIES, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 26: NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SIZE FOR LABORATORIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 27: ASIA-PACIFIC: HPV TESTING AND PAP TEST MARKET SIZE FOR LABORATORIES, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 28: HPV TESTING AND PAP TEST MARKET SIZE FOR HOSPITALS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 29: NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SIZE FOR HOSPITALS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 30: ASIA-PACIFIC: HPV TESTING AND PAP TEST MARKET SIZE FOR HOSPITALS, BY REGION/COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 31: HPV TESTING AND PAP TEST MARKET SIZE FOR PHYSICIAN'S OFFICES AND CLINICS, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 32: NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SIZE FOR PHYSICIAN'S OFFICES AND CLINICS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 33: ASIA-PACIFIC: HPV TESTING AND PAP TEST MARKET SIZE FOR PHYSICIAN'S OFFICES AND CLINICS, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 34: HPV TESTING AND PAP TEST MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)
  • TABLE 35: HPV TESTING AND PAP TEST MARKET SIZE, BY REGION, 2013-2020 (MILLION TESTS)
  • TABLE 36: NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 37: NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 38: NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (MILLION TESTS)
  • TABLE 39: NORTH AMERICA: HPV TESTING MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 40: NORTH AMERICA: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 41: NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 42: U.S.: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 43: U.S.: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 44: U.S.: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 45: CANADA: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 46: CANADA: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 47: CANADA: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 48: EUROPE: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 49: EUROPE: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (MILLION TESTS)
  • TABLE 50: EUROPE: HPV TESTING MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 51: EUROPE: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 52: EUROPE: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 53: ASIA-PACIFIC: HPV TESTING AND PAP TEST MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
  • TABLE 54: ASIA-PACIFIC: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 55: ASIA-PACIFIC: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (MILLION TESTS)
  • TABLE 56: ASIA-PACIFIC: HPV TESTING MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 57: ASIA-PACIFIC: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 58: ASIA-PACIFIC: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 59: JAPAN: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 60: JAPAN: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 61: JAPAN: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 62: CHINA: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 63: CHINA: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 64: CHINA: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 65: INDIA: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 66: INDIA: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 67: INDIA: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 68: ROAPAC: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 69: ROAPAC: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 70: ROAPAC: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 71: ROW: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 72: ROW: HPV TESTING AND PAP TEST MARKET SIZE, BY TEST TYPE, 2013-2020 (MILLION TESTS)
  • TABLE 73: ROW: HPV TESTING MARKET SIZE, BY TEST TYPE, 2013-2020 (USD MILLION)
  • TABLE 74: ROW: PAP TEST MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION)
  • TABLE 75: ROW: HPV TESTING AND PAP TEST MARKET SIZE, BY END USER, 2013-2020 (USD MILLION)
  • TABLE 76: PRODUCT APPROVALS AND LICENSES 2013-2015
  • TABLE 77: NEW PRODUCT LAUNCHES, 2012-2015
  • TABLE 78: AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2012-2015
  • TABLE 79: ACQUISITIONS, 2012-2015
  • TABLE 80: EXPANSIONS, 2012-2015

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION AND DATA TRIANGULATION
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANIES, DESIGNATION, AND REGION
  • FIGURE 4: HPV TESTING AND PAP TEST MARKET SNAPSHOT (2015 VS. 2020)
  • FIGURE 5: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2015 VS. 2020
  • FIGURE 6: THE HOSPITALS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 7: CERVICAL CANCER SCREENING SEGMENT WILL CONTINUE TO DOMINATE THE PAP TEST MARKET DURING THE FORECAST PERIOD
  • FIGURE 8: NEW PRODUCT LAUNCH IS THE MOST DOMINANT STRATEGY ADOPTED BY MARKET PLAYERS
  • FIGURE 9: RISING INCIDENCES OF CERVICAL CANCER AND INCREASING AWARENESS OF CERVICAL CANCER SCREENING ARE FACTORS DRIVING MARKET GROWTH
  • FIGURE 10: HPV TESTING WILL BE THE FASTEST-GROWING SEGMENT DURING THE FORECAST PERIOD
  • FIGURE 11: LABORATORIES SEGMENT DOMINATES THE HPV TESTING MARKET IN 2015
  • FIGURE 12: THE HPV TESTING AND PAP TEST MARKET IN NORTH AMERICA IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 13: HPV TESTING AND PAP TEST MARKET ANALYSIS
  • FIGURE 14: HPV TESTING AND PAP TEST MARKET: DRIVERS, RESTRAINTS, OPPORTUNITY, AND CHALLENGE
  • FIGURE 15: CERVICAL CANCER INCIDENCES AND MORTALITY: GLOBAL FORECAST, 2012-2020
  • FIGURE 16: HPV TESTING SEGMENT TO OUTGROW PAP TESTING DURING THE FORECAST PERIOD
  • FIGURE 17: PRIMARY HPV TESTING SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 18: NORTH AMERICA IS PROJECTED TO DOMINATE THE HPV TESTING MARKET DURING FORECAST PERIOD
  • FIGURE 19: NORTH AMERICA IS EXPECTED TO DOMINATE THE PAP TEST MARKET DURING THE FORECAST PERIOD
  • FIGURE 20: CERVICAL CANCER SCREENING IS A MAJOR APPLICATION OF THE HPV TESTING AND PAP TEST MARKET
  • FIGURE 21: NORTH AMERICA IS EXPECTED TO DOMINATE THE PAP TEST MARKET FOR CERVICAL CANCER SCREENING
  • FIGURE 22: NORTH AMERICA IS EXPECTED TO DOMINATE THE VAGINAL CANCER SCREENING MARKET
  • FIGURE 23: LABORATORIES ARE THE MAJOR END USERS OF THE HPV TESTING AND PAP TEST MARKET
  • FIGURE 24: NORTH AMERICA EXHIBITS HIGHEST GROWTH POTENTIAL IN THE LABORATORIES END USER SEGMENT
  • FIGURE 25: NORTH AMERICA IS PROJECTED TO DOMINATE THE HOSPITALS MARKET DURING THE FORECAST PERIOD
  • FIGURE 26: NORTH AMERICA: HIGHEST GROWTH POTENTIAL IN THE PHYSICIANS' OFFICES AND CLINICS END-USER SEGMENT
  • FIGURE 27: GEOGRAPHIC SNAPSHOT: NORTH AMERICA WILL BE THE FASTEST-GROWING REGION IN THE HPV TESTING AND PAP TEST MARKET BY 2020
  • FIGURE 28: NORTH AMERICAN MARKET FOR HPV TESTING SHOWS SIGNIFICANT GROWTH OPPORTUNITIES
  • FIGURE 29: THE HPV TESTING AND PAP TEST MARKET IN NORTH AMERICA IS PROJECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 30: NORTH AMERICA HPV TESTING AND PAP TEST MARKET SNAPSHOT
  • FIGURE 31: THE U.S. IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE NORTH AMERICA HPV TESTING AND PAP TEST MARKET DURING THE FORECAST PERIOD
  • FIGURE 32: THE FOLLOW-UP HPV TESTING SEGMENT IS EXPECTED TO DOMINATE THE NORTH AMERICA HPV TESTING MARKET
  • FIGURE 33: THE HOSPITALS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 34: THE HPV TESTING SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 35: EUROPEAN HPV TESTING AND PAP TEST MARKET SNAPSHOT
  • FIGURE 36: THE HOSPITALS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 37: JAPAN IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE IN THE ASIA-PACIFIC HPV TESTING AND PAP TEST MARKET
  • FIGURE 38: THE LABORATORIES SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN 2015
  • FIGURE 39: THE CERVICAL CANCER SCREENING SEGMENT ACCOUNTED FOR THE LARGEST SHARE IN 2015
  • FIGURE 40: THE HPV TESTING SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 41: THE HOSPITALS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 42: THE HOSPITALS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 43: NEW PRODUCT LAUNCHES, PRODUCT APPROVALS, AGREEMENTS, AND ACQUISITIONS HAVE BEEN THE KEY STRATEGIES ADOPTED IN THE LAST THREE YEARS
  • FIGURE 44: GLOBAL HPV TESTING AND PAP TEST MARKET SHARE, BY KEY PLAYERS, 2014
  • FIGURE 45: BATTLE FOR MARKET SHARE: PRODUCT APPROVALS AND LICENSES, NEW PRODUCT LAUNCH, AGREEMENTS & ACQUISITIONS HAVE BEEN THE KEY STRATEGIES
  • FIGURE 46: GEOGRAPHIC REVENUE MIX OF THE TOP FIVE MARKET PLAYERS
  • FIGURE 47: ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 48: QIAGEN N.V.: COMPANY SNAPSHOT
  • FIGURE 49: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 50: HOLOGIC, INC.: COMPANY SNAPSHOT
  • FIGURE 51: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 52: QUEST DIAGNOSTICS: COMPANY SNAPSHOT
Back to Top